# Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma

> **NCT00041587** · PHASE1,PHASE2 · COMPLETED · sponsor: **INSYS Therapeutics Inc** · enrollment: 80 (—)

## Conditions studied

- Malignant Glioma
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Mixed Oligoastrocytoma

## Interventions

- **DRUG:** IL13-PE38QQR
- **PROCEDURE:** targeted fusion protein therapy
- **PROCEDURE:** surgery

## Key facts

- **NCT ID:** NCT00041587
- **Lead sponsor:** INSYS Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2006-06
- **Final completion:** 2007-07
- **Target enrollment:** 80 (—)
- **Last updated:** 2011-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00041587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00041587, "Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00041587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*